Sorafenib for the treatment of unresectable hepatocellular carcinoma (2008)
Junji FuruseDepartment of Internal Medicine, Medical Oncology, School of Medicine, Kyorin UniversityAbstract: Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived...
Zytoon, Ashraf Anas, Ishii, Hiroshi, Murakami, Koji, El-Kholy, Mohamed Ramdan, Furuse, Junji, El-Dorry, Ahmed, ...
Background Despite the high complete necrosis rate of radiofrequency ablation (RFA), tumor recurrence, either local tumor recurrence or new tumor formation, remains a significant problem. Purpose of...
Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer (2007)
Nakachi, Kohei, Furuse, Junji, Ishii, Hiroshi, Suzuki, Ei-ichiro, Yoshino, Masahiro
Objective The purpose of this study was to identify prognostic factors in patients with gemcitabine-refractory pancreatic cancer and to determine criteria for selecting candidates for second-line...
Yonemoto, Naohiro, Furuse, Junji, Okusaka, Takuji, Yamao, Kenji, Funakoshi, Akihiro, Ohkawa, Shinichi, ...
Background This study examined the effect of five systemic chemotherapy regimens on survival in patients with unresectable biliary tract cancer (BTC) as compared with the best supportive care (BSC). ...
Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer (2007)
Nakachi, Kohei, Furuse, Junji, Ishii, Hiroshi, Suzuki, Ei-ichiro, Yoshino, Masahiro
Objective The purpose of this study was to identify prognostic factors in patients with gemcitabine-refractory pancreatic cancer and to determine criteria for selecting candidates for second-line...
Okusaka, Takuji, Ishii, Hiroshi, Funakoshi, Akihiro, Ueno, Hideki, Furuse, Junji, Sumii, Toshihiko
Background: In an effort to improve efficacy of single-agent gemcitabine in pancreatic cancer, several studies have examined the effects of 5-FU combined with gemcitabine. However, no studies to date...
Furuse, Junji, Okusaka, Takuji, Funakoshi, Akihiro, Yamao, Kenji, Nagase, Michitaka, Ishii, Hiroshi, ...
Background: Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of...
Furuse, Junji, Okusaka, Takuji, Funakoshi, Akihiro, Yamao, Kenji, Nagase, Michitaka, Ishii, Hiroshi, ...
Background: Standard chemotherapy for advanced biliary tract cancer has not been established. The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of...
Okusaka, Takuji, Ishii, Hiroshi, Funakoshi, Akihiro, Ueno, Hideki, Furuse, Junji, Sumii, Toshihiko
Background: In an effort to improve efficacy of single-agent gemcitabine in pancreatic cancer, several studies have examined the effects of 5-FU combined with gemcitabine. However, no studies to date...
Primary Tumor of Pancreatic Cancer as a Measurable Target Lesion in Chemotherapy Trials (2005)
Ishii, Hiroshi, Furuse, Junji, Nakachi, Kouhei, Suzuki, Ei-ichiro, Yoshino, Masahiro
Background: It is unclear whether primary pancreatic cancer (PC) tumors can be accepted as measurable target lesions in chemotherapy trials. We reviewed recent PC patients to clarify the significance...
A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)
Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi
Background: Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...
Ishii, Hiroshi, Furuse, Junji, Kinoshita, Taira, Konishi, Masaru, Nakagohri, Toshio, Takahashi, Shinichiro, ...
Background: Recent advances in cancer chemotherapy have increased not only the survival rate but also the treatment cost, although there has been little interest in cost analyses in Japan. Method:...
Primary Tumor of Pancreatic Cancer as a Measurable Target Lesion in Chemotherapy Trials (2005)
Ishii, Hiroshi, Furuse, Junji, Nakachi, Kouhei, Suzuki, Ei-ichiro, Yoshino, Masahiro
Background: It is unclear whether primary pancreatic cancer (PC) tumors can be accepted as measurable target lesions in chemotherapy trials. We reviewed recent PC patients to clarify the significance...
Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...
Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients with...
Ishii, Hiroshi, Furuse, Junji, Kinoshita, Taira, Konishi, Masaru, Nakagohri, Toshio, Takahashi, Shinichiro, ...
Background: Recent advances in cancer chemotherapy have increased not only the survival rate but also the treatment cost, although there has been little interest in cost analyses in Japan. Method:...
A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)
Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi
Background: Uracil–tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...
Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...
Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients...
A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma (2005)
Ikeda, Masafumi, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Furuse, Junji, Ishii, Hiroshi
Background: Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. However, its activity in biliary tract carcinoma has not been fully evaluated. The...
Ishii, Hiroshi, Furuse, Junji, Kinoshita, Taira, Konishi, Masaru, Nakagohri, Toshio, Takahashi, Shinichiro, ...
Background: Recent advances in cancer chemotherapy have increased not only the survival rate but also the treatment cost, although there has been little interest in cost analyses in Japan. Method:...
Primary Tumor of Pancreatic Cancer as a Measurable Target Lesion in Chemotherapy Trials (2005)
Ishii, Hiroshi, Furuse, Junji, Nakachi, Kouhei, Suzuki, Ei-ichiro, Yoshino, Masahiro
Background: It is unclear whether primary pancreatic cancer (PC) tumors can be accepted as measurable target lesions in chemotherapy trials. We reviewed recent PC patients to clarify the significance...
Furuse, Junji, Ishii, Hiroshi, Okusaka, Takuji, Nagase, Michitaka, Nakachi, Kohei, Ueno, Hideki, ...
Objective: The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m2/min) on a weekly schedule to Japanese patients with...
Ishii, Hiroshi, Furuse, Junji, Kinoshita, Taira, Konishi, Masaru, Nakagohri, Toshio, Takahashi, Shinichiro, ...
Background: There is no standard treatment for patients with extrahepatic spread from hepatocellular carcinoma. The aim of this retrospective study was to identify candidates for aggressive...
Ishii, Hiroshi, Furuse, Junji, Nagase, Michitaka, Maru, Yasushi, Yoshino, Masahiro, Hayashi, Takayuki
Background: Hepatic arterial infusion of zinostatin stimalamer and lipiodol emulsion shows a moderate activity against hepatocellular carcinoma. However, the anti-tumor activity of zinostatin...
Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer (2001)
Okada, Shuichi, Ueno, Hideki, Okusaka, Takuji, Ikeda, Masafumi, Furuse, Junji, Maru, Yasushi
Background: Gemcitabine is the most promising new agent currently being tested in pancreatic cancer. The present study was conducted to confirm the tolerability of a weekly schedule of gemcitabine at...
Sorafenib for the treatment of unresectable hepatocellular carcinoma
Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for obtaining both anti-tumor...